Sick Economics

Searching For Healthy Profits In The Stock Market

Sick Economics. Healthcare Investing Tips & Analysis. Big Pharma, Biotech, Medical Devices, Healthcare REITs & More.

SickEconomics.com is a sister site of SickDividends.com

SICK PICKS


Our favorite biotech shares and healthcare investments in today’s stock market. Highlighting companies that stand to profit through medical innovation, mismatches in share price to market potential, or just plain great economics. (Stocks may be owned by the Sick Economist, or other commentators on this page.)

VRTX

Vertex Pharmaceuticals is an example of a young biopharma company with big ambitions. The cash flow positive firm has made its name with breakthrough medicines in the field of Cystic Fibrosis, and is now close to broadening its commercial offerings into blood diseases, kidney disease, and pain management. If you wonder what Eli Lilly looked like 100 years ago, before it was a giant, this could be it.

finviz dynamic chart for VRTX

Click On Chart To Expand

CERT

This cashflow positive business aims to accelerate the drug discovery process by offering biosimulation services to major pharmaceutical firms such as Eli Lilly, Merck, Pfizer. Certera offers software and services that allow researches to more accurately model the effects of a new drug on the human body. Certera’s revenue has grown for five years in a row, and management believes that they have barely begun to scratch the surface of what can be achieved through biosimulation.

finviz dynamic chart for CERT

Click On Chart To Expand

IONS

Ionis pharmaceutical ($IONS) is a commercial stage biotech company seeking to apply recent advances in RNA technology to the worlds of neurology and cardiology. Although the company is not yet profitable, revenue grew by 40% in the latest quarterly report, and Ionis has 9 different stage III studies in it’s pipeline. The company boasts marquee pharmaceutical partners such as GSK, Astra Zeneca and Novartis. A recent deal with Roche to develop novel RNA therapies for Alzheimer’s and Huntington’s Disease brims with promise. With more than $2 billion in cash, IONIS is well positioned to ride out the current dryspell facing the whole biotech market. Strong funding, a blossoming pipeline, and a stable of prestigious partners should make IONIS appealing to any biotech investor.

finviz dynamic chart for IONS

Click On Chart To Expand

BIOTECH INVESTING


Biotech investing means betting on scientific innovation. This space is dedicated to small cap biotech stocks, leading edge biotechnology research, and small stocks that have flown under the radar. Let’s talk about how you can turn innovation into profit.

IOVANCE BIOTHERAPEUTICS & GOOD MATH

  A common refrain is “math is the language of nature.”  Did you know that…

SUMMIT THERAPEUTICS: CAN LIGHTNING STRIKE TWICE?

  In life, it is rare for lightning to strike a person. According to the…

IONIS PHARMACEUTICALS: THE LITTLE BIG PHARMA?

  What, exactly, separates a biotech company from a “Big Pharma” company? What are the…

HEALTHCARE SERVICES


Modern healthcare equities comprise an intricate ecosystem of healthcare service providers in addition to makers of medicines and devices. Investment in insurance companies, hospitals, clinics, and many other service providers have yielded substantial profits while helping millions of people.

SHOULD NEOGENOMICS LABORATORIES BE ON THE RADAR FOR GROWTH INVESTORS?

Neogenomics Laboratories ($NEO) is a lab dedicated solely to the diagnosis and study of cancer….

HCA AND THE FUTURE OF HEALTHCARE

By Aidan Asbill, Equity Analyst   As we discussed in the last article, HCA Healthcare…

IS GOOGLE A HEALTHCARE COMPANY?

By Aidan Asbill, Securities Analyst    Google is one of the biggest technology companies in…

HEALTHCARE REITs


Healthcare Real Estate (REITs) are high yielding stocks in the healthcare industry. You can invest in nursing homes, medical office buildings and research labs. Learn a profitable and easy way to invest in healthcare real estate.

HIGH YIELD HEALTHCARE: AN INTERVIEW WITH JUSSI ASKOLA

Jussi Askola is the President of Leonberg Capital, a boutique investment research firm specializing in…

3 HEALTHCARE REITS FOR STEADY RETIREMENT INCOME

With the Fed reluctant to raise interest rates further, those in or near retirement may…

JUST RED, NOT DEAD

Red is usually not a good color in the investing world. When a company is…

CAPITAL EQUIPMENT


Robots, radiation cannons, and molecular imaging machines aren’t just the healthcare tech of the future; they are also the source of investor profit for many decades to come. Big machines can mean big profits for equity investors.

MEDICAL ROBOTICS: A PROFIT MACHINE?

By Tammy Tran, Equity Analyst    Although medical robotics has been a field that has…

WILL INTUITIVE SURGICAL BE PERMANENTLY CRIPPLED BY THE PANDEMIC?

Intuitive Surgical has revolutionized the minimally invasive, robotic-assisted surgical space with their FDA approved da…

LARRY CULP’S ART OF THE DEAL: 3 BUSINESS LESSONS FROM GE’S BIOPHARMACEUTICAL SALE

In a surprise move, GE has agreed to sell it’s BioPharmaceutical Division to Danaher for…

sick economics

You understand that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. You further understand that none of the bloggers, information providers, app providers, or their affiliates are advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content published on the Site may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to the investment needs of any specific person. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Site will not contain a list or description of relevant risk factors.

The Site is not intended to provide tax, legal, insurance or investment advice, and nothing on the Site should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Sick Economics or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.

ACCEPT